SEARCH

SEARCH BY CITATION

6 References

  • 1
    Ripsin, C. M., Keenan, J. M., Jacobs, D. R., Jr., Elmer, P. J., et al., Oat products and lipid lowering. A meta-analysis. JAMA 1992, 267, 33173325.
  • 2
    Kerckhoffs, D. A., Brouns, F., Hornstra, G., Mensink, R. P., Effects on the human serum lipoprotein profile of beta-glucan, soy protein and isoflavones, plant sterols and stanols, garlic and tocotrienols. J. Nutr. 2002, 132, 24942505.
  • 3
    Tiwari, U., Cummins, E., Meta-analysis of the effect of beta-glucan intake on blood cholesterol and glucose levels. Nutrition 2011, 27, 10081016.
  • 4
    FDA, FDA allows whole oat foods to make health claim on reducing the risk of heart disease. FDA Talk Paper, T97-5, January 21, 1997.
  • 5
    European Food Safety Authority (EFSA). Scientific Opinion on the substantiation of health claims related to beta-glucans and maintenance of normal blood cholesterol concentrations (ID 754, 757, 801, 1465, 2934) and maintenance or achievement of a normal body weight (ID 820, 823) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. http://www.efsa.europa.eu/en/scdocs/doc/s1254.pdf, accessed September 2010.
  • 6
    Lusis, A. J., Atherosclerosis. Nature 2000, 407, 233241.
  • 7
    Libby, P., Aikawa, M., Schonbeck, U., Cholesterol and atherosclerosis. Biochim. Biophys. Acta 2000, 1529, 299309.
  • 8
    Ruxton, C., Derbyshire, E., A systematic review of the association between cardiovascular risk factors and regular consumption of oats. Br. Food J. 2008, 110, 11191132.
  • 9
    Libby, P., Ridker, P. M., Hansson, G. K., Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473, 317325.
  • 10
    Hansson, G. K., Hermansson, A., The immune system in atherosclerosis. Nat. Immunol. 2011, 12, 204212.
  • 11
    Libby, P., Ridker, P. M., Hansson, G. K., Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 2009, 54, 21292138.
  • 12
    Chait, A., Han, Y. C., Oram, J. F., Heinecke, J. W., Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J. Lipid Res. 2005, 46, 389403.
  • 13
    Balakumar, P., Kathuria, S., Taneja, G., Kalra, S. et al., Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J. Mol. Cell. Cardiol. 2012, 52, 8392.
  • 14
    Sitia, S., Tomasoni, L., Atzeni, F., Ambrosio, G. et al., From endothelial dysfunction to atherosclerosis. Autoimmun. Rev. 2010, 9, 830834.
  • 15
    Zhou, M., Robards, K., Glennie-Holmes, M., Helliwell, S., Oat lipids. JAOCS 1999, 76, 159169.
  • 16
    Ryan, D., Kendall, M., Robards, K., Bioactivity of oats as it relates to cardiovascular disease. Nutr. Res. Rev. 2007, 20, 147162.
  • 17
    Drzikova, B., Dongowski, G, Gebhardt, E, Habel, A, The composition of dietary fibre-rich extrudates from oat affects bile acid binding and fermentation in vitro. Food Chem. 2005, 90, 181192.
  • 18
    Peterson, D., Oat antioxidants. J. Cereal Sci. 2001, 33, 115129.
  • 19
    Chen, C. Y., Milbury, P. E., Collins, F. W., Blumberg, J. B., Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. J. Nutr. 2007, 137, 13751382.
  • 20
    Chen, C. Y., Milbury, P. E., Kwak, H. K., Collins, F. W. et al., Avenanthramides and phenolic acids from oats are bioavailable and act synergistically with vitamin C to enhance hamster and human LDL resistance to oxidation. J. Nutr. 2004, 134, 14591466.
  • 21
    Koenig, R. T., Dickman, J. R., Wise, M. L., Ji, L. L., Avenanthramides are bioavailable and accumulate in hepatic, cardiac, and skeletal muscle tissue following oral gavage in rats. J. Agric. Food Chem. 2011, 59, 64386443.
  • 22
    Handelman, G. J., Cao, G., Walter, M. F., Nightingale, Z. D. et al., Antioxidant capacity of oat (Avena sativa L.) extracts. 1. Inhibition of low-density lipoprotein oxidation and oxygen radical absorbance capacity. J. Agric. Food Chem. 1999, 47, 48884893.
  • 23
    de Groot, A. P., Luyken, R., Pikaar, N. A., Cholesterol-lowering effects of rolled oats. Lancet 1963, 282, 303304.
  • 24
    Brennan, C. S., Cleary, L. J., The potential use of cereal (1/3,1/4)-b-D-glucans as functional food ingredients. J. Cereal Sci. 2005, 42, 113.
  • 25
    Kelly, S. A., Summerbell, C. D., Brynes, A., Whittaker, V. et al., Wholegrain cereals for coronary heart disease. Cochrane Database Syst. Rev. 2007, 18, CD005051.
  • 26
    Malkki, Y., Torronen, R., Pelkonen, K., Myllymaki, O. et al., Effects of oat-bran concentrate on rat serum lipids and liver fat infiltration. Br. J. Nutr. 1993, 70, 767776.
  • 27
    De Schrijver, R., Fremaut, D., Verheyen, A., Cholesterol-lowering effects and utilization of protein, lipid, fiber and energy in rats fed unprocessed and baked oat bran. J. Nutr. 1992, 122, 13181324.
  • 28
    Delaney, B., Nicolosi, R. J., Wilson, T. A., Carlson, T. et al., Beta-glucan fractions from barley and oats are similarly antiatherogenic in hypercholesterolemic Syrian golden hamsters. J. Nutr. 2003, 133, 468475.
  • 29
    Czerwinski, J., Bartnikowska, E., Leontowicz, H., Lange, E. et al., Oat (Avena sativa L.) and amaranth (Amaranthus hypochondriacus) meals positively affect plasma lipid profile in rats fed cholesterol-containing diets. J. Nutr. Biochem. 2004, 15, 622629.
  • 30
    Andersson, K. E., Immerstrand, T., Sward, K., Bergenstahl, B. et al., Effects of oats on plasma cholesterol and lipoproteins in C57BL/6 mice are substrain specific. Br. J. Nutr. 2010, 103, 513521.
  • 31
    Lund, E. K., Gee, J. M., Brown, J. C., Wood, P. J. et al., Effect of oat gum on the physical properties of the gastrointestinal contents and on the uptake of D-galactose and cholesterol by rat small intestine in vitro. Br. J. Nutr. 1989, 62, 91101.
  • 32
    Andersson, M., Ellegard, L., Andersson, H., Oat bran stimulates bile acid synthesis within 8 h as measured by 7alpha-hydroxy-4-cholesten-3-one. Am. J. Clin. Nutr. 2002, 76, 11111116.
  • 33
    Yang, J. L., Kim, Y. H., Lee, H. S., Lee, M. S. et al., Barley beta-glucan lowers serum cholesterol based on the up-regulation of cholesterol 7alpha-hydroxylase activity and mRNA abundance in cholesterol-fed rats. J. Nutr. Sci. Vitaminol. (Tokyo) 2003, 49, 381387.
  • 34
    Wood, P. J., Braaten, J. T., Scott, F. W., Riedel, K. D. et al., Effect of dose and modification of viscous properties of oat gum on plasma glucose and insulin following an oral glucose load. Br. J. Nutr. 1994, 72, 731743.
  • 35
    Drzikova, B., Dongowski, G., Gebhardt, E., Dietary fibre-rich oat-based products affect serum lipids, microbiota, formation of short-chain fatty acids and steroids in rats. Br. J. Nutr. 2005, 94, 10121025.
  • 36
    Demigne, C., Morand, C., Levrat, M. A., Besson, C. et al., Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. Br. J. Nutr. 1995, 74, 209219.
  • 37
    Levrat, M. A., Favier, M. L., Moundras, C., Remesy, C. et al., Role of dietary propionic acid and bile acid excretion in the hypocholesterolemic effects of oligosaccharides in rats. J. Nutr. 1994, 124, 531538.
  • 38
    Immerstrand, T., Andersson, K. E., Wange, C., Rascon, A. et al., Effects of oat bran, processed to different molecular weights of beta-glucan, on plasma lipids and caecal formation of SCFA in mice. Br. J. Nutr. 2010, 104, 364373.
  • 39
    Liu, S., Yang, N., Hou, Z., Yao, Y. et al., Antioxidant effects of oats avenanthramides on human serum. Agric. Sci. China 2011, 10, 13011305.
  • 40
    Charlton-Menys, V., Durrington, P. N., Human cholesterol metabolism and therapeutic molecules. Exp. Physiol. 2008, 93, 2742.
  • 41
    Andersson, K. E., Svedberg, K. A., Lindholm, M. W., Oste, R. et al., Oats (Avena sativa) reduce atherogenesis in LDL-receptor-deficient mice. Atherosclerosis 2010, 212, 9399.
  • 42
    Sur, R., Nigam, A., Grote, D., Liebel, F. et al., Avenanthramides, polyphenols from oats, exhibit anti-inflammatory and anti-itch activity. Arch. Dermatol. Res. 2008, 300, 569574.
  • 43
    Theuwissen, E., Plat, J., Mensink, R. P., Consumption of oat beta-glucan with or without plant stanols did not influence inflammatory markers in hypercholesterolemic subjects. Mol. Nutr. Food Res. 2009, 53, 370376.
  • 44
    Queenan, K. M., Stewart, M. L., Smith, K. N., Thomas, W. et al., Concentrated oat beta-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. Nutr. J. 2007, 6, 6.
  • 45
    Libby, P., Ridker, P. M., Maseri, A., Inflammation and atherosclerosis. Circulation 2002, 105, 11351143.
  • 46
    Liu, L., Zubik, L., Collins, F. W., Marko, M. et al., The antiatherogenic potential of oat phenolic compounds. Atherosclerosis 2004, 175, 3949.
  • 47
    Koga, T., Kwan, P., Zubik, L., Ameho, C. et al., Vitamin E supplementation suppresses macrophage accumulation and endothelial cell expression of adhesion molecules in the aorta of hypercholesterolemic rabbits. Atherosclerosis 2004, 176, 265272.
  • 48
    Murray, P. J., Wynn, T. A., Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11, 723737.
  • 49
    Woollard, K. J., Geissmann, F., Monocytes in atherosclerosis: subsets and functions. Nat. Rev. Cardiol. 2010, 7, 7786.
  • 50
    Thorp, E., Subramanian, M., Tabas, I., The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis. Eur. J. Immunol. 2011, 41, 25152518.
  • 51
    Yun, C. H., Estrada, A., Van Kessel, A., Park, B. C. et al., Beta-glucan, extracted from oat, enhances disease resistance against bacterial and parasitic infections. FEMS Immunol. Med. Microbiol. 2003, 35, 6775.
  • 52
    Zadernowski, R., Nowak-Polakowska, H., Rashed, A. A., The influence of heat treatment on the activity of lipo- and hydrophilic components of oat grain. J. Food Process. Preserv. 1999, 23, 177191.
  • 53
    Singh, U., Devaraj, S., Jialal, I., Vitamin E, oxidative stress, and inflammation. Annu. Rev. Nutr. 2005, 25, 151174.
  • 54
    Maki, K. C., Galant, R., Samuel, P., Tesser, J. et al., Effects of consuming foods containing oat beta-glucan on blood pressure, carbohydrate metabolism and biomarkers of oxidative stress in men and women with elevated blood pressure. Eur. J. Clin. Nutr. 2007, 61, 786795.
  • 55
    Gray, D. A., Clark, M. J., Baux, C., Bunting, J. P. et al., Antioxidant activity of oat extracts added to human LDL particles and in free radical trapping assays. J. Cereal Sci. 2002, 36, 209218.
  • 56
    Emmons, C. L., Peterson, D. M., Antioxidant activity and phenolic contents of oat groats and hulls. Cereal Chem. 1999, 76, 902906.
  • 57
    Ji, L. L., Lay, D., Chung, E., Fu, Y. et al., Effects of avenanthramides on oxidant generation and antioxidant enzyme activity in exercised rats. Nutr. Res. 2003, 23, 15791590.
  • 58
    Ren, Y., Yang, X., Niu, X., Liu, S. et al., Chemical characterization of the avenanthramide-rich extract from oat and its effect on D-galactose-induced oxidative stress in mice. J. Agric. Food Chem. 2011, 59, 206211.
  • 59
    Lopez-Bote, C. J., Sanz, M., Rey, A., Castaño, A. et al., Lower lipid oxidation in the muscle of rabbits fed diets containing oats. Anim. Feed Sci. Technol. 1998, 70, 19.
  • 60
    Katz, D. L., Nawaz, H., Boukhalil, J., Giannamore, V. et al., Acute effects of oats and vitamin E on endothelial responses to ingested fat. Am. J. Prev. Med. 2001, 20, 124129.
  • 61
    Kuhlencordt, P. J., Gyurko, R., Han, F., Scherrer-Crosbie, M. et al., Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001, 104, 448454.
  • 62
    Nie, L., Wise, M. L., Peterson, D. M., Meydani, M., Avenanthramide, a polyphenol from oats, inhibits vascular smooth muscle cell proliferation and enhances nitric oxide production. Atherosclerosis 2006, 186, 260266.
  • 63
    Katz, D. L., Nawaz, H., Boukhalil, J., Chan, W. et al., Effects of oat and wheat cereals on endothelial responses. Prev. Med. 2001, 33, 476484.
  • 64
    Katz, D. L., Evans, M. A., Chan, W., Nawaz, H. et al., Oats, antioxidants and endothelial function in overweight, dyslipidemic adults. J. Am. Coll. Nutr. 2004, 23, 397403.
  • 65
    Keenan, J. M., Pins, J. J., Frazel, C., Moran, A. et al., Oat ingestion reduces systolic and diastolic blood pressure in patients with mild or borderline hypertension: a pilot trial. J. Fam. Pract. 2002, 51, 369.
  • 66
    Saltzman, E., Das, S. K., Lichtenstein, A. H., Dallal, G. E. et al., An oat-containing hypocaloric diet reduces systolic blood pressure and improves lipid profile beyond effects of weight loss in men and women. J. Nutr. 2001, 131, 14651470.
  • 67
    Pins, J. J., Geleva, D., Keenan, J. M., Frazel, C. et al., Do whole-grain oat cereals reduce the need for antihypertensive medications and improve blood pressure control? J. Fam. Pract. 2002, 51, 353359.
  • 68
    Meydani, M., Potential health benefits of avenanthramides of oats. Nutr. Rev. 2009, 67, 731735.
  • 69
    Takahashi, A., Taniguchi, T., Ishikawa, Y., Yokoyama, M., Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53. Circ. Res. 1999, 84, 543550.
  • 70
    Tamai, H., Katoh, K., Yamaguchi, T., Hayakawa, H. et al., The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am. Heart J. 2002, 143, 506513.
  • 71
    Holmes, D. R., Jr., Savage, M., LaBlanche, J. M., Grip, L. et al., Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002, 106, 12431250.
  • 72
    Eussen, S. R., Rompelberg, C. J., Andersson, K. E., Klungel, O. H. et al., Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice. Pharmacol. Res. 2011, 64, 3643.
  • 73
    Wilson, T. A., Idreis, H. M., Taylor, C. M., Nicolosi, R. J., Whole fat rice bran reduces the development of early aortic atherosclerosis in hypercholesterolemic hamsters compared with wheat bran. Nutr. Res. 2002, 22, 13191322.
  • 74
    Meir, K. S., Leitersdorf, E., Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 10061014.
  • 75
    Cyrus, T., Yao, Y., Rokach, J., Tang, L. X. et al., Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions. Circulation 2003, 107, 521523.
  • 76
    Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J. et al., Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004, 350, 14951504.
  • 77
    Lloyd-Jones, D. M., Hong, Y., Labarthe, D., Mozaffarian, D. et al., Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond. Circulation 2010, 121, 586613.
  • 78
    Lopez-Garcia, E., Schulze, M. B., Fung, T. T., Meigs, J. B. et al., Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am. J. Clin. Nutr. 2004, 80, 10291035.
  • 79
    Erkkila, A. T., Herrington, D. M., Mozaffarian, D., Lichtenstein, A. H., Cereal fiber and whole-grain intake are associated with reduced progression of coronary-artery atherosclerosis in postmenopausal women with coronary artery disease. Am. Heart J. 2005, 150, 94101.
  • 80
    Trowell, H., Ischemic heart disease and dietary fiber. Am. J. Clin. Nutr. 1972, 25, 926932.
  • 81
    Anderson, J. W., Hanna, T. J., Peng, X., Kryscio, R. J., Whole grain foods and heart disease risk. J. Am. Coll. Nutr. 2000, 19, 291S-299S.
  • 82
    Truswell, A. S., Cereal grains and coronary heart disease. Eur. J. Clin. Nutr. 2002, 56, 114.